Vericel Corp (VCEL) stock

VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/30240% above fair value

$56.96−0.46 (-0.80%)

Close on Nov 13, 2026Market cap $2.92BP/E 96.5Yield –

Vericel price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Vericel's price to sales ratio was 9.9× on Nov 11, 2026, against 7.9× a year earlier. Over the last 5 years it ranged from 5.8× to 12.7×, with a median of 9.0×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	9.9×	+2.9
2025	Dec 31, 2025	7.0×	−4.9
2024	Dec 31, 2024	11.9×	+2.8
2023	Dec 29, 2023	9.2×	+1.4
2022	Dec 30, 2022	7.8×	−4.1
2021	Dec 31, 2021	11.9×	+0.1
2020	Dec 31, 2020	11.8×	+4.8
2019	Dec 31, 2019	7.1×	−2.0
2018	Dec 31, 2018	9.1×	+6.1
2017	Dec 29, 2017	3.0×	+1.6
2016	Dec 30, 2016	1.3×	+0.1
2015	Dec 31, 2015	1.2×	−3.9
2014	Dec 31, 2014	5.1×	−460.2
2013	Dec 31, 2013	465.4×	−32.0
2012	Feb 29, 2012	497.4×	+66.7
2010	Sep 30, 2010	430.7×	+187.1
2009	Dec 31, 2009	243.6×	–